Actavis Rejects Mylan Offer [REPORT] – ValueWalk Premium
Actavis logo

Actavis Rejects Mylan Offer [REPORT]

Generic drug maker Actavis Inc (NYSE:ACT) is reported to have spurned a $15 billion cash and stock acquisition offer from Mylan Inc. (NASDAQ:MYL).

According to Bloomberg

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0